OncoMatch/Clinical Trials/NCT06925464
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
Is NCT06925464 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies CD7 CAR-T cells infusion for t-cell non-hodgkin lymphoma.
Treatment: CD7 CAR-T cells infusion — This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD7 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD7 CAR T cell bridging to HSCT in the treatment of r/r T-NHL. The primary endpoint is the type and incidence of dose limiting toxicity (DLT) within 21 days after CD7 CAR-T cell infusion. A total of 36 subjects is estimated to be enrolled.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD7 overexpression (positive)
Relapsed or refractory CD7-positive T-cell lymphomas
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: chemotherapy
treated with with standard chemotherapy, with poor prognosis from currently available treatments at and no available treatment options (e.g., HSCT or chemotherapy)
Lab requirements
Kidney function
serum creatinine and/or urea nitrogen < 1.5 times the normal value
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06925464 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received chemotherapy.
Does this trial require CD7?
Yes, CD7 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 14 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages